Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
[PR Newswire] – TARRYTOWN, N.Y., Feb. 24, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company’s supplemental Biologics License Applicati moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to […]